Search

Clinical Pharmacology & Therapeutics (CPT) is an established voice of the discipline, a trusted source of new knowledge showcasing discovery, translation and application of novel therapeutic paradigms to advance the management of patients and populations. Identifying, evaluating, prioritizing and disseminating the best science along the discovery-development-regulatory-utilization continuum are responsibilities shared through peer review. To enhance the uniformity of this essential component of quality assurance and innovation, and maximize the value of the journal and its contents to authors, reviewers, and the readership, we review key concepts concerning peer review as it specifically relates to CPT. Even if individual researchers are prone to falling in love with their own theories, the broader process of peer review and institutionalized skepticism are designed to ensure that, eventually, the best ideas prevail.Chris Mooney

Biological advances have radically expanded our insights into the underpinnings of health and disease. New knowledge has formed the substrate for translation - expedited in turn by the biotechnology and pharmaceutical industry into novel therapeutic solutions impacting the management of patients and populations. Indeed, this Bioinnovation Enterprise has become the dominant growth sector in drug development and the engine driving the translation of breakthrough therapies worldwide. This annual Therapeutic Innovations issue highlights recent exceptional advances by the Bioinnovation Enterprise in translating molecular insights in pathobiology into transformative therapies.

It has been nearly ten years since we joined the editorial organization of Clinical Pharmacology & Therapeutics (CPT), as part of the American Society for Clinical Pharmacology and Therapeutics (ASCPT) family. During that tenure, the primary mandate has been the growth of CPT, recognized as one of the key voices of the discipline and the Society. Set goals were realized in concert with a strong editorial team, a diverse editorial board, a dedicated editorial staff, and outstanding authors, leveraging a leading publishing infrastructure and responding to the needs of a global readership, expanding membership, and the discipline as a whole. The impending decade anniversary, and the transition to a new publisher, offers a natural juncture to reflect on progress, and chart plans for the future of the Journal.

The revolution in scientific innovation, driven by the engines of enabling technologies, is increasingly capable of deconstructing complex disease processes for the express purpose of reconstructing patient-specific solutions. These revelations in biological mechanisms provide the pressure points of opportunity for radical discovery and development to advance modern health care. Principles of mechanism-based discovery and their translation into therapeutic algorithms will, however, be challenged in the near term by emerging global public health crises that currently have no immediate solutions: chronic diseases, obesity, antibiotic-resistant infections, dementia, depression. The threat of these pandemics (multiplied in an increasingly aging population), the global burden of disease they represent, and their worldwide assault on human capital underscore the importance of continued and accelerated investments in science-propelled practice advancement, converting new knowledge into delivery of tangible health solutions. In that context, this annual issue of CPT on therapeutics innovations highlights remarkable recent successes in the discovery–development paradigm translating molecular innovations into diagnostic and therapeutic realities that transform the management of disease, impacting global health. Clinical Pharmacology & Therapeutics (2013); 95 1, 3–7. doi:10.1038/clpt.2013.211

Enabling science and information technologies has catalyzed a surge of biological, clinical, demographic, health services, and comparative-effectiveness data. While accelerating the deconvolution of complex pathophysiological, medical, social, and environmental networks and systems, these platforms have produced informational quanta devoid of contextualization. Therapeutic innovation is thus now challenged with moving beyond knowledge generation and curation to integrated solution-seeking paradigms that organize functionally related information, producing system-level insights into health and disease for optimized patient-centered outcomes. This annual issue on therapeutics innovations highlights emerging considerations for the generation and hierarchical organization of scientific and clinical information and its translation to advancing next-generation disease management. Clinical Pharmacology & Therapeutics (2013); 93 1, 3–7. doi:10.1038/clpt.2012.208

Major advances in fundamental mechanisms underlying (patho)physiology over the past decades have generated a robust therapeutic armamentarium; exemplifi ed by synthetic hormones, multigenerational antibiotics, and recombinant vaccines, off ering eff ective interventions across a range of diseases. Th e exponential ascent of the new biology has transformed the comprehension of human health and disease and revolutionized technology; redefi ning clinical pharmacology in the context of discovery and translation, and the role of the clinical pharmacologist as the bridge between the laboratory and the patient, and thence to the population at large. Th e integration of cross-disciplinary concepts emerging from discovery and driving therapeutic solutions has imposed an evolutionary pressure on clinical pharmacology to focus on the identifi cation and application of tools for prognosis, prediction, cure, and, ultimately, prevention in pursuit of personalized medicine. Th e promise of clinical pharmacology and its impact on the future of therapeutics, in the emerging areas of combinatorial pharmacogenetics, targeted interference with disease, as well as stem cell–based tissue engineering and regeneration (to name a few), extends